rrx-001 and Lung-Neoplasms

rrx-001 has been researched along with Lung-Neoplasms* in 4 studies

Reviews

1 review(s) available for rrx-001 and Lung-Neoplasms

ArticleYear
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.
    Oncotarget, 2016, Jun-28, Volume: 7, Issue:26

    Like Chinese boxes nesting inside each other, the classification of non-small cell lung cancer (NSCLC) is subdivided into smaller and smaller subtypes on the basis of histological and molecular attributes. The latter characterizes NSCLC by its molecular alterations and the identification of inhibitors that target these cancer-specific "driver" mutations. Despite the initial promise of precision-guided therapies to inhibit a finer and finer array of molecular subcategories, despite even the curative potential of immunotherapeutic checkpoint blockade, in particular, casualties still abound and true clinical success stories are few and far between; the ever-present, if sometimes unmentioned, "elephant in the room", is the acquisition of resistance, which, sooner or later, rears its ugly head to undermine treatment success and shorten survival. Emerging data suggests that epigenetic therapies are able to reprogram the aberrant tumor-associated epigenome and 'tame the beast of resistance', thereby prolonging survival. This article reviews the role of epigenetic dysregulation in NSCLC, explores PFS2 as a possible surrogate endpoint, briefly mentions possible biomarkers and highlights combinatorial treatment epigenetic strategies to "prime" tumors and reverse resistance.

    Topics: Antibodies, Monoclonal; Azacitidine; Azetidines; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; CpG Islands; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Histones; Humans; Hydralazine; Immunotherapy; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Recurrence, Local; Nitro Compounds; Nivolumab; Prognosis; Pyridines; Treatment Outcome; Valproic Acid

2016

Trials

1 trial(s) available for rrx-001 and Lung-Neoplasms

ArticleYear
REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer.
    Future oncology (London, England), 2019, Volume: 15, Issue:30

    RRx-001 is a cysteine-directed anticancer alkylating agent with activity in a Phase II study in platinum refractory small cell lung cancer. Here, we describe the design of REPLATINUM, an open-label, Phase III trial. 120 patients with previously platinum-treated small cell lung cancer in third line will be randomized 1:1 to receive RRx-001 followed by four cycles of a platinum doublet, and then alternating cycles of RRx-001 and single agent platinum until progression versus four cycles of a platinum doublet. At radiologic progression on the platinum doublet, patients may cross over to the RRx-001 arm. Primary objective: to demonstrate superior progression-free survival in the RRx-001 population. Secondary objectives: to demonstrate superiority for overall survival and objective response rate. Clinical Trial registration: NCT03699956.

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Carboplatin; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nitro Compounds; Small Cell Lung Carcinoma; Treatment Outcome; Young Adult

2019

Other Studies

2 other study(ies) available for rrx-001 and Lung-Neoplasms

ArticleYear
Nanomedicine-based co-delivery of a calcium channel inhibitor and a small molecule targeting CD47 for lung cancer immunotherapy.
    Nature communications, 2023, 11-11, Volume: 14, Issue:1

    Pro-tumoral macrophages in lung tumors present a significant challenge in immunotherapy. Here, we introduce a pH-responsive nanomedicine approach for activating anti-tumoral macrophages and dendritic cells. Using a layered double hydroxide nanosheet carrier, we co-deliver a T-type calcium channel inhibitor (TTA-Q6) and a CD47 inhibitor (RRX-001) into lung tumors. In the tumor acidic environment, TTA-Q6 is released, disrupting cancer cell calcium uptake, causing endoplasmic reticulum stress and inducing calreticulin transfer to the cell surface. Surface calreticulin activates macrophages and triggers dendritic cell maturation, promoting effective antigen presentation and therefore activating antitumor T cells. Simultaneously, RRX-001 reduces CD47 protein levels, aiding in preventing immune escape by calreticulin-rich cancer cells. In lung tumor models in male mice, this combined approach shows anti-tumor effects and immunity against tumor re-exposure, highlighting its potential for lung cancer immunotherapy.

    Topics: Animals; Calreticulin; CD47 Antigen; Immunotherapy; Lung Neoplasms; Male; Mice; Nanomedicine; Neoplasms; Phagocytosis

2023
Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.
    Oncology research and treatment, 2016, Volume: 39, Issue:11

    The response to first-line platinum doublets (cisplatin/etoposide) in small-cell lung cancer (SCLC) predicts the probability of subsequent response to second-line therapy. In general, the longer-lived the responses in first line, the better the outcome in second line, with the opposite prognosis for shorter-lived responses. Resistant SCLC is defined as relapse within 90 days of platinum-doublet treatment, and predictably correlates with shortened survival compared with sensitive disease, defined as relapse after 90 days.. We present a patient with platinum-resistant SCLC that was rechallenged with cisplatin/etoposide in the context of the clinical trial TRIPLE THREAT (NCT02489903) after treatment with, and progression on, the resistance-reversing anticancer agent RRx-001.. The prolonged partial response of this platinum-resistant SCLC to reintroduced carboplatin/etoposide after RRx-001 belies and contradicts the prevailing orthodoxy in oncology that rechallenge with chemotherapy after the emergence of resistance is an exercise in futility and risk, which potentially exposes patients to toxicity without benefit.

    Topics: Antineoplastic Combined Chemotherapy Protocols; Azetidines; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Nitro Compounds; Treatment Outcome

2016